Irach Taraporewala
Chief Executive Officer chez EOM PHARMACEUTICALS HOLDINGS, INC.
Profil
Irach B.
Taraporewala is the founder.
He founded Ohr Pharmaceutical, Inc. in 2008, where he held the title of President, Director & Chief Technology Officer.
He also founded Sitara Pharmaceutical Consulting LLC in 2016, where he held the title of President & Managing Member.
Dr. Taraporewala is also the founder of DepYmed, Inc. He currently holds two positions.
Since 2020, he has been the Chief Executive Officer & Director at EOM Pharmaceuticals, Inc. He is also the President, Chief Executive Officer & Director at EOM Pharmaceuticals Holdings, Inc. In his former positions, Dr. Taraporewala served as the President, Chief Executive Officer & Director at ImmunoCellular Therapeutics Ltd.
He was the Chief Executive Officer & Director at NanoViricides, Inc. from 2018 to 2019.
From 1998 to 2004, he worked at Advanced Viral Research Corp.
as the Director-Chemistry & Quality Control.
He also held the position of Vice President at Mystic Pharmaceuticals, Inc. In terms of education, Dr. Taraporewala completed his undergraduate and graduate studies at the University of Mumbai.
He obtained his doctorate degree from the Philadelphia College of Pharmacy.
Postes actifs de Irach Taraporewala
| Sociétés | Poste | Début |
|---|---|---|
| EOM PHARMACEUTICALS HOLDINGS, INC. | Chief Executive Officer | 01/05/2020 |
EOM Pharmaceuticals, Inc.
 EOM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of EOM Pharmaceuticals Holdings, Inc., EOM Pharmaceuticals, Inc. is a privately held, clinical-stage company focused on developing novel drugs to improve the quality of life for patients with debilitating and sometimes deadly diseases. The company is based in Montvale, NJ. The company's mission is to pursue innovative approaches with small molecule therapeutics to address urgent and unmet medical needs. EOM's pipeline includes the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illnesses caused by intense inflammatory immune reactions, including COVID-19, influenza, and cancer cachexia. Additionally, EOM is working on an advanced formulation of EOM147, the first potential topically administered eye drop for treating retinal diseases. The company was founded by Shalom Z. Hirschman and Eli Goldberger, and Irach B. Taraporewala has been the CEO since 2020. EOM Pharmaceuticals was acquired by ImmunoCellular Therapeutics Ltd. on December 02, 2021. | Chief Executive Officer | 01/05/2020 |
Anciens postes connus de Irach Taraporewala
| Sociétés | Poste | Fin |
|---|---|---|
| Sitara Pharmaceutical Consulting LLC | Founder | 01/01/2021 |
| NANOVIRICIDES, INC. | Chief Executive Officer | 01/02/2019 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Chief Executive Officer | 06/08/2015 |
Advanced Viral Research Corp.
 Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Corporate Officer/Principal | 01/01/2004 |
DepYmed, Inc.
 DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Founder | - |
Formation de Irach Taraporewala
| University of Mumbai | Graduate Degree |
| Philadelphia College of Pharmacy | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NANOVIRICIDES, INC. | Health Technology |
| EOM PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
Mystic Pharmaceuticals, Inc.
 Mystic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mystic Pharmaceuticals, Inc. manufactures and wholesales pharmaceutical and biological products. The private company was founded in 2003 and is based in Austin, TX. | Health Technology |
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
DepYmed, Inc.
DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Health Technology |
| Sitara Pharmaceutical Consulting LLC | |
EOM Pharmaceuticals, Inc.
EOM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of EOM Pharmaceuticals Holdings, Inc., EOM Pharmaceuticals, Inc. is a privately held, clinical-stage company focused on developing novel drugs to improve the quality of life for patients with debilitating and sometimes deadly diseases. The company is based in Montvale, NJ. The company's mission is to pursue innovative approaches with small molecule therapeutics to address urgent and unmet medical needs. EOM's pipeline includes the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illnesses caused by intense inflammatory immune reactions, including COVID-19, influenza, and cancer cachexia. Additionally, EOM is working on an advanced formulation of EOM147, the first potential topically administered eye drop for treating retinal diseases. The company was founded by Shalom Z. Hirschman and Eli Goldberger, and Irach B. Taraporewala has been the CEO since 2020. EOM Pharmaceuticals was acquired by ImmunoCellular Therapeutics Ltd. on December 02, 2021. | Health Technology |
